Meda AB (publ), Interim Report January - September 2008


Meda AB (publ), Interim Report January - September 2008

• The Group's net sales reached SEK 7,515 million (5,821), a 29% increase
compared to the previous year.

• EBITDA rose by 32% to SEK 2,616 million (1,981), [1]   thus yielding a 34.8%
margin (34.0).

• Operating profit rose to SEK 1,826 million (1,323).

• Profit after tax climbed to SEK 808 million (749).
• Profit per share reached SEK 3.12 (3.20). Profit per share, excluding
non-recurring profit impact rose to SEK 3.12 (3.00). [2]


• Full-year forecast for 2008, excl. acquired operations
(i.e. excl. effects from acquisitions of Valent's operations, Roche's product
portfolio, and any restructuring costs)"The Meda Group estimates it will reach sales of about SEK 10,000 million for
2008. EBITDA for 2008 is estimated to reach SEK 3,300 million, including
significant pre-launch expenses in the US for Astepro and Onsolis amounting to
about SEK 100 million during Q4.”

Valeant's acquired operations and Roche's product portfolio that will be
entirely consolidated during Q4 are projected to supply the Meda Group with
about SEK 1,600 million in sales annually, which is not included in the
forecast.


For more information, contact:

Anders Larnholt, Investor Relations
Telephone: +46-8-630 19 62, +46-709-458 878

[1] Excluding restructuring costs of SEK 118 million, due to the 3M pharma
division acquisition.
[2] Excluding the above non-recurring effect, and excluding one-off revenue in
net financial items, SEK 65 million, from Q1 2007. Calculated using a 33.8%
standard tax rate, corresponding to the tax rate for January-September 2007.
Also excluding a positive one-off effect of SEK 83 million on tax expense for
January-September 2007, which is the result of revaluation of deferred tax
liabilities following corporation tax cuts in Germany.

Attachments

10312010.pdf